Russell Investments Group Ltd. Has $85.43 Million Stake in Edwards Lifesciences Co. (NYSE:EW)

Russell Investments Group Ltd. lifted its position in shares of Edwards Lifesciences Co. (NYSE:EW - Free Report) by 15.9% during the fourth quarter, according to its most recent Form 13F filing with the SEC. The institutional investor owned 1,120,025 shares of the medical research company's stock after purchasing an additional 153,726 shares during the period. Russell Investments Group Ltd. owned about 0.18% of Edwards Lifesciences worth $85,430,000 at the end of the most recent reporting period.

A number of other hedge funds and other institutional investors have also made changes to their positions in EW. Asset Management One Co. Ltd. increased its position in Edwards Lifesciences by 0.5% in the 3rd quarter. Asset Management One Co. Ltd. now owns 323,224 shares of the medical research company's stock valued at $22,393,000 after acquiring an additional 1,622 shares during the period. Livforsakringsbolaget Skandia Omsesidigt increased its position in Edwards Lifesciences by 63.9% in the 3rd quarter. Livforsakringsbolaget Skandia Omsesidigt now owns 7,440 shares of the medical research company's stock valued at $515,000 after acquiring an additional 2,900 shares during the period. Arthur M. Cohen & Associates LLC increased its position in Edwards Lifesciences by 3.1% in the 3rd quarter. Arthur M. Cohen & Associates LLC now owns 22,023 shares of the medical research company's stock valued at $1,526,000 after acquiring an additional 662 shares during the period. Sumitomo Life Insurance Co. increased its position in Edwards Lifesciences by 3.4% in the 3rd quarter. Sumitomo Life Insurance Co. now owns 25,516 shares of the medical research company's stock valued at $1,768,000 after acquiring an additional 833 shares during the period. Finally, Commonwealth Equity Services LLC increased its position in Edwards Lifesciences by 7.3% in the 3rd quarter. Commonwealth Equity Services LLC now owns 163,984 shares of the medical research company's stock valued at $11,361,000 after acquiring an additional 11,117 shares during the period. Institutional investors and hedge funds own 79.46% of the company's stock.

Insider Transactions at Edwards Lifesciences

In other news, Director Michael A. Mussallem sold 29,350 shares of the company's stock in a transaction on Monday, March 4th. The stock was sold at an average price of $86.67, for a total transaction of $2,543,764.50. Following the completion of the sale, the director now directly owns 4,486 shares in the company, valued at approximately $388,801.62. The transaction was disclosed in a legal filing with the SEC, which is available at this link. In other news, Director Michael A. Mussallem sold 29,350 shares of the company's stock in a transaction on Monday, March 4th. The stock was sold at an average price of $86.67, for a total transaction of $2,543,764.50. Following the completion of the sale, the director now directly owns 4,486 shares in the company, valued at approximately $388,801.62. The transaction was disclosed in a legal filing with the SEC, which is available at this link. Also, VP Jean-Luc M. Lemercier sold 14,400 shares of the company's stock in a transaction on Monday, April 8th. The stock was sold at an average price of $92.32, for a total value of $1,329,408.00. Following the sale, the vice president now owns 173,849 shares of the company's stock, valued at $16,049,739.68. The disclosure for this sale can be found here. Insiders sold a total of 194,004 shares of company stock worth $17,166,254 in the last ninety days. Insiders own 1.29% of the company's stock.

Wall Street Analysts Forecast Growth

EW has been the topic of several recent analyst reports. OTR Global upgraded Edwards Lifesciences from a "mixed" rating to a "positive" rating in a research report on Tuesday, March 26th. Royal Bank of Canada boosted their target price on Edwards Lifesciences from $95.00 to $101.00 and gave the stock an "outperform" rating in a research report on Monday, April 15th. Bank of America upgraded Edwards Lifesciences from a "neutral" rating to a "buy" rating in a research report on Thursday, March 7th. Wells Fargo & Company boosted their target price on Edwards Lifesciences from $94.00 to $99.00 and gave the stock an "overweight" rating in a research report on Friday. Finally, Evercore ISI dropped their target price on Edwards Lifesciences from $92.00 to $89.00 and set an "in-line" rating on the stock in a research report on Friday. One research analyst has rated the stock with a sell rating, seven have given a hold rating and ten have assigned a buy rating to the company. Based on data from MarketBeat, the company presently has an average rating of "Moderate Buy" and a consensus target price of $93.33.

Edwards Lifesciences Trading Down 1.8 %

Shares of Edwards Lifesciences stock traded down $1.58 during trading hours on Friday, reaching $86.43. 4,979,943 shares of the company's stock were exchanged, compared to its average volume of 2,883,164. Edwards Lifesciences Co. has a 52-week low of $60.57 and a 52-week high of $96.12. The firm has a market capitalization of $52.02 billion, a price-to-earnings ratio of 37.25, a price-to-earnings-growth ratio of 4.29 and a beta of 1.05. The company has a fifty day moving average of $90.28 and a 200-day moving average of $78.95. The company has a current ratio of 3.38, a quick ratio of 2.40 and a debt-to-equity ratio of 0.09.

Edwards Lifesciences (NYSE:EW - Get Free Report) last issued its quarterly earnings results on Thursday, April 25th. The medical research company reported $0.66 earnings per share for the quarter, topping analysts' consensus estimates of $0.64 by $0.02. Edwards Lifesciences had a return on equity of 23.34% and a net margin of 23.01%. The company had revenue of $1.60 billion for the quarter, compared to analyst estimates of $1.58 billion. Sell-side analysts forecast that Edwards Lifesciences Co. will post 2.76 EPS for the current fiscal year.

Edwards Lifesciences Company Profile

Edwards Lifesciences Corporation provides products and technologies for structural heart disease and critical care monitoring in the United States, Europe, Japan, and internationally. It offers transcatheter heart valve replacement products for the minimally invasive replacement of aortic heart valves under the Edwards SAPIEN family of valves system; and transcatheter heart valve repair and replacement products to treat mitral and tricuspid valve diseases under the PASCAL PRECISION and Cardioband names.